Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling
Dingxiao Liu, … , Chou-Long Huang, Massimo Attanasio
Dingxiao Liu, … , Chou-Long Huang, Massimo Attanasio
Published May 10, 2021
Citation Information: JCI Insight. 2021;6(9):e146959. https://doi.org/10.1172/jci.insight.146959.
View: Text | PDF
Research Article Nephrology

Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling

  • Text
  • PDF
Abstract

Loss of function of the lipid kinase diacylglycerol kinase ε (DGKε), encoded by the gene DGKE, causes a form of atypical hemolytic uremic syndrome that is not related to abnormalities of the alternative pathway of the complement, by mechanisms that are not understood. By generating a potentially novel endothelial specific Dgke-knockout mouse, we demonstrate that loss of Dgke in the endothelium results in impaired signaling downstream of VEGFR2 due to cellular shortage of phosphatidylinositol 4,5-biphosphate. Mechanistically, we found that, in the absence of DGKε in the endothelium, Akt fails to be activated upon VEGFR2 stimulation, resulting in defective induction of the enzyme cyclooxygenase 2 and production of prostaglandin E2 (PGE2). Treating the endothelial specific Dgke-knockout mice with a stable PGE2 analog was sufficient to reverse the clinical manifestations of thrombotic microangiopathy and proteinuria, possibly by suppressing the expression of matrix metalloproteinase 2 through PGE2-dependent upregulation of the chemokine receptor CXCR4. Our study reveals a complex array of autocrine signaling events downstream of VEGFR2 that are mediated by PGE2, that control endothelial activation and thrombogenic state, and that result in abnormalities of the glomerular filtration barrier.

Authors

Dingxiao Liu, Qiong Ding, Dao-Fu Dai, Biswajit Padhy, Manasa K. Nayak, Can Li, Madison Purvis, Heng Jin, Chang Shu, Anil K. Chauhan, Chou-Long Huang, Massimo Attanasio

×

Figure 1

VEGFR2-dependent Akt activation is compromised in DGKE-knockdown human umbilical vein epithelial cells.

Options: View larger image (or click on image) Download as PowerPoint
VEGFR2-dependent Akt activation is compromised in DGKE-knockdown human u...
(A) Schematic representation of the phosphoinositide cycle and of some of the enzymes involved in the cycle (boxes). Red arrows point to the major enzymes (PI3K and phospholipase C γ, PLCγ) activated downstream of VEGFR2. Black arrows represent generation of PtdIns(1,4,5) P3 (PIP3) and Ca2+ downstream of PI3K and PLCγ, respectively, and activation of Akt. The common substrate of PI3K and PLCγ, PIP2, required for Akt activation is highlighted in red. DGKε is highlighted in red. (B) Efficiency of the sh-RNA knockdown in HUVECs measured by quantitative PCR (Q-PCR) compared with nontargeted control (sh-GFP) cells. Control: nontransfected cells. (C) Western blot showing impaired Akt activation (phosphorylation of threonine 308 and serine 473) in the shRNA-knockdown HUVECs upon VEGFA stimulation, compared with nontargeted control cells. (D) Expression of Cox2, measured by Q-PCR, is not induced in DGKE-knockdown HUVECs compared with nontargeted control cells stimulated with VEGFA. (E) Western blots showing that impaired Akt activation in the sh-RNA knockdown HUVECs upon VEGFA stimulation is partially reversed by PIP2 and PIP3 supplementation. (F) Changes in intracellular Ca2+ concentrations after VEGFA supplementation in DGKE-knockdown HUVECs, in DGKE-knockdown HUVECs after PIP2 supplementation, and in nontargeted HUVEC controls over time, measured by Fura-2 AM fluorescence. Data are from 3–4 independent experiments and are presented as mean ± SD. **: P < 0.01 by 1-way ANOVA in B and by Student’s t test in D. Each data point represents 1 experiment. PTEN, phosphatase and tensin homolog; pAKT, phosphorylated Akt; DeltaR: fluorescence ratio as 340 nm/380 nm.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts